<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320500">
  <stage>Registered</stage>
  <submitdate>14/01/2010</submitdate>
  <approvaldate>6/03/2006</approvaldate>
  <actrnumber>ACTRN12610000070033</actrnumber>
  <trial_identification>
    <studytitle>A randomized trial to compare efficacy and safety of cyclosporin-prednisone versus mycophenolate mofetil-prednisone, 3 months after renal transplantation.</studytitle>
    <scientifictitle>A randomized trial to compare efficacy and safety of cyclosporin-prednisone versus mycophenolate mofetil-prednisone, 3 months after renal transplantation.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Cochrane Renal Group 030600045</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>mycophenolate mofetil 2g per day and prednisone 0.15 mg/kg, per day from month 3 to 12 post graft. Both drugs: oral capsules</interventions>
    <comparator>cyclosporine 3-8 mg/kg per day adjusted for blood trough levels between 100 and 300 mcg/L and prednisone 0.15 mg/kg per day from month 3 to 12 post graft. Both drugs: oral capsules</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of biopsy-proven acute allograft rejection during the first post-transplant year</outcome>
      <timepoint>12 months post transplant</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum creatinine</outcome>
      <timepoint>12 months post transplant (once monthly from month 3 to 12 post graft)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>graft and patient survival (the date of the graft failure was defined as the day when dialysis was restarted or patient death)</outcome>
      <timepoint>12 months post transplant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chronic Allograft Dysfunction Index (CADI)</outcome>
      <timepoint>12 months post transplant (comparison of 2 timepoints biopsies, at 3 and 12 months post graft respectively)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) First renal transplantation from a deceased donor under a triple drug regimen (cyclosporine + mycophenolate mofetil + prednisone)

2) No acute rejection episode during the first 3 months post graft (time of randomisation)

3) Patients who gave their informed consent and are able to understand the scope of the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Living donor, re-transplantation

2) Panel ractive antibodies &gt; 30%

3) Serum creatinine &gt; 2.5 mg/dl (222 umol/l)

4) Cyclosporine toxicity at the time of randomisation (3 months post graft)

5) Patients with generalized infection at the time of transplantation

6) Women in child-bearing age who do not plan to use efficient contraception

7) Age of donor &gt; 65</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/1999</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>108</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Protocole Hospitalier de Recherche Clinique (PHRC)</primarysponsorname>
    <primarysponsoraddress>French Minister of Health

Ministere de la Sante et des Sports
14, avenue Duquesne
75350 PARIS 07 SP</primarysponsoraddress>
    <primarysponsorcountry>France</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Protocole Hospitalier de Recherche Clinique (PHRC)</fundingname>
      <fundingaddress>French Minister of Health

Ministere de la Sante et des Sports
14, avenue Duquesne
75350 PARIS 07 SP</fundingaddress>
      <fundingcountry>France</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Santelys Association</sponsorname>
      <sponsoraddress>Santelys - Parc Eurasante - 351 rue Ambroise Pare - 59120 LOOS - FRANCE</sponsoraddress>
      <sponsorcountry>France</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study was to compare the incidence of acute rejection in de novo low risk renal transplant patients after an early cyclosporin or mycophenolate mofetil withdrawal (3 months post graft) from an initial triple drug regimen (cyclosporin + mycophenolate + prednisone).
The primary outcome was the incidence of biopsy proven acute rejection (BPAR) episodes at 12 months post graft.
We tested the hypothesis of a unilateral equivalence of an incidence of 10% BPAR in the cyclosporin group. With a non inferiority limit of 15% the number of patients to include was 98. To take into account a 10% rate of non assessable patients for the statistical analysis, 108 patients were enrolled (54 in each group).</summary>
    <trialwebsite />
    <publication>Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. M Hazzan, M Labalette, MC Copin, F Glowacki, F Provot, FR Pruvot, C Noel. J Am Soc Nephrol. 2005 ; 16 : 2509-2516
Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. M Hazzan, D Buob, M Labalette, F Provot, F Glowacki, M Hoffmann, MC Copin, C NoÃ«l. Transplantation. 2006 ; 15 : 657-662</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof, Marc, HAZZAN</name>
      <address>Nephrology, Regional Hospital of Lille, Hopital Huriez, CHRU de Lille. 59037 Lille cedex (France)</address>
      <phone>+33 3 20 44 67 70</phone>
      <fax />
      <email>mhazzan@gmail.com</email>
      <country>France</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof, Christian, NOEL</name>
      <address>Head, Nephrology, Regional Hospital of Lille, Hopital Huriez, CHRU de Lille. 59037 Lille cedex (France)</address>
      <phone>+33 3 20 44 41 42</phone>
      <fax />
      <email>christian.noel@chru-lille.fr</email>
      <country>France</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof, Marc, HAZZAN</name>
      <address>Nephrology, Regional Hospital of Lille, Hopital Huriez, CHRU de Lille. 59037 Lille cedex (France)</address>
      <phone>+33 3 20 44 67 70</phone>
      <fax>+33 3 20 44 58 72</fax>
      <email>mhazzan@gmail.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>